How pharma can utilise the power of Nordic real-world data
The meteoric rise of real-world evidence presents new opportunities and new challenges.
The healthcare industry is experiencing a paradigm shift as real-world evidence (RWE) derived from real-world data (RWD) continues to revolutionise the world of drug development and commercialisation worldwide.
Many practitioners point to the opportunities of RWE to rectify certain limitations associated with randomised clinical trials (RCTs). These include representativeness of the underlying patient population, lack of head-to-head comparators, short follow-up and the ethical concerns of randomising patients.
Check out the rest of this feature here